Atorvastatin reduces lipid accumulation in the liver by activating protein kinase A-mediated phosphorylation of perilipin 5

• DOI: 10.1016/j.bbalip.2017.09.007
• Publication Date: 2017-09-13T04:32:59Z
• Authors: Xing Gao; Yang Nan; Yuanlin Zhao; Yuan Yuan; Bincheng Ren; Chao Sun; Kaiyu Cao; Ming Yu; Xuyang Feng; Jing Ye
• Keywords: Male; Mice, Knockout; 0303 health sciences; Lipolysis; Intracellular Signaling Peptides and Proteins; Mutation, Missense; Muscle Proteins; Cyclic AMP-Dependent Protein Kinases; Dietary Fats; Mice; 03 medical and health sciences; Amino Acid Substitution; Liver; Non-alcoholic Fatty Liver Disease; Atorvastatin; Animals; Phosphorylation; Triglycerides

Statins have been proven to be effective in treating non-alcoholic fatty liver disease (NAFLD). Recently, it was reported that statins decreased the hepatic expression of perilipin 5 (Plin5), a lipid droplet (LD)-associated protein, which plays critical roles in regulating lipid accumulation and lipolysis in liver. However, the function and regulation mechanism of Plin5 have not yet been well-established in NAFLD treatment with statins. In this study, we observed that atorvastatin moderately reduced the expression of Plin5 in livers without changing the protein level of Plin5 in the hepatic LD fraction of mice fed with high-fat diet (HFD). Intriguingly, atorvastatin stimulated the PKA-mediated phosphorylation of Plin5 and reduced the triglyceride (TG) accumulation in hepatocytes with overexpression of wide type (Plin5-WT) compared to serine-155 mutant Plin5 (Plin5-S155A). Moreover, PKA-stimulated FA release of purified LDs carrying Plin5-WT but not Plin5-S155A. Glucagon, a PKA activator, stimulated the phosphorylation of Plin5-WT and inhibited its interaction with CGI-58. The results indicated that atorvastatin promoted lipolysis and reduced TG accumulation in the liver by increasing PKA-mediated phosphorylation of Plin5. This new mechanism of lipid-lowering effects of atorvastatin might provide a new strategy for NAFLD treatment.